Literature DB >> 2809257

Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis.

M M Mustafa1, O Ramilo, J Mertsola, R C Risser, B Beutler, E J Hansen, G H McCracken.   

Abstract

By use of an experimental lapin model, the effect of ceftriaxone therapy on inflammation during Hemophilus influenzae type b (Hib) meningitis was evaluated. Meningitis was induced by intracisternal inoculation of 2 x 10(4) to 2 x 10(5) colony-forming units of Hib. Administration of ceftriaxone 6 h after infection provoked rapid bacterial lysis associated with greatly increased concentrations of bacteria-free endotoxin (lipooligosaccharide) and tumor necrosis factor alpha (TNF) in the cerebrospinal fluid (CSF). CSF TNF activity peaked 2 h after initiation of antibiotic therapy (24.4 +/- 2 ng/ml), was significantly higher than that in untreated controls (1.4 +/- 1.1 ng/ml; P less than .05), and was associated with a substantially increased inflammatory response as reflected by higher CSF white blood cell count (24,500 +/- 8,151 vs. 1,920 +/- 644 in untreated controls; P less than .05), lower glucose, and higher protein and lactate concentrations. Simultaneous administration of dexamethasone with antibiotic therapy resulted in a significant reduction in CSF TNF activity that was associated with a substantial reduction in CSF white blood cell count. These data suggest that initiation of ceftriaxone therapy in experimental Hib meningitis exacerbates the meningeal inflammatory response, which can be modulated by concurrent dexamethasone administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809257     DOI: 10.1093/infdis/160.5.818

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

Review 1.  Dexamethasone in bacterial meningitis: to use or not to use?

Authors:  A Kaul; S Chandwani
Journal:  Indian J Pediatr       Date:  1996 Sep-Oct       Impact factor: 1.967

2.  Effects of polysaccharide fucoidin on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit.

Authors:  C Granert; J Raud; A Waage; L Lindquist
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  Hearing impairment after bacterial meningitis: a review.

Authors:  H M Fortnum
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 4.  Should we use dexamethasone in meningitis? The Meningitis Working Party of the British Paediatric Immunology and Infectious Diseases Group.

Authors: 
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

Review 5.  Dexamethasone in bacterial meningitis.

Authors:  S K Kabra; P Kumar; I C Verma
Journal:  Indian J Pediatr       Date:  1991 Jul-Aug       Impact factor: 1.967

6.  Endotoxin induced damage to the cochlea in guinea pigs.

Authors:  M J Tarlow; S D Comis; M P Osborne
Journal:  Arch Dis Child       Date:  1991-02       Impact factor: 3.791

Review 7.  Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy.

Authors:  A M van Furth; J J Roord; R van Furth
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Dexamethasone and bacterial meningitis in Pakistan.

Authors:  S A Qazi; M A Khan; N Mughal; M Ahmad; B Joomro; Y Sakata; N Kuriya; T Matsuishi; K A Abbas; F Yamashita
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

9.  Protein synthesis-dependent induction of interleukin-1 beta by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cells.

Authors:  D W Kimberlin; S A Willis; G H McCracken; P D Nisen
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.

Authors:  X Sáez-Llorens; O Ramilo; M M Mustafa; J Mertsola; C de Alba; E Hansen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.